Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01025388

Acronym

CEPHEUS

Enrollment

4053

Registered

2009-12-03

Start date

2009-11-30

Completion date

2010-05-31

Last updated

2013-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Hypercholesterolemia, The study is focusing on the undertreatment of hypercholesterolemia

Brief summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome (according to NCEP III definition). In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. · * Subject must sign informed consent

Exclusion criteria

* Subjects who are unwilling or unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, overall and by country.	6 months- One visit only, no follow up visits.

Secondary

Measure	Time frame
The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations - Primary/secondary prevention patients - Patients with metabolic syndrome (according to NCEP III definition).	6 months - One visit only, no follow up visits.
The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines / national guidelines, in the following sub-populations:-Primary/secondary prevention patients -Patients with metabolic syndrome.	6 months- One visit only, no follow up visits.

Countries

Saudi Arabia

Outcome results